Diagnostic and Therapeutic Approach to Multisystem Inflammatory Syndrome and Similar Condition
- Autores: Emami A.1, Yeganeh S.2, Mohammadi H.3, Shahbazi T.2
-
Afiliações:
- Hamadan University of Medical Sciences
- Neurosurgery Research Group (NRG), Student Research Committee, Hamadan University of Medical Sciences
- Student Research Committee, Hamadan University of Medical Sciences, School of Medicine
- Edição: Volume 143, Nº 3 (2023)
- Páginas: 218-228
- Seção: Articles
- URL: https://journals.rcsi.science/0042-1324/article/view/138947
- DOI: https://doi.org/10.31857/S0042132423030055
- EDN: https://elibrary.ru/QPXEKW
- ID: 138947
Citar
Resumo
Multisystem inflammatory syndrome (MIS-C) can occur in kids, who have severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). Clinically, characteristics of MIS-C are manifested by two or more involved organ systems, fever, severe illness, laboratory-evidenced inflammation, and laboratory or epidemiologically e-videnced infection with SARS-CoV-2. MIS-C has several traits with Kawasaki illness, subsequent hemophagocytic lymphohistiocytosis/macrophage activation syndrome, and toxic shock syndrome. The association between MIS-C and infection with SARS-CoV-2 shows the cause of post-infectious immunological dysregulation. Given the likelihood of rapid clinical deterioration, it is recommended to handle MIS-C patients in a pediatric critical care unit. Depending on the clinical presentation, a certain immunomodulatory therapy is advised. More research is needed to determine the connection between MIS-C and the immunological reaction to SARS-CoV-2 vaccines that are currently being developed. Numerous therapeutic methods have been developed for the treatment of COVID-19-associated MIS in children (MIS-C), the full elucidation of its etiology requires further studies. Here, we carefully review and summarize the previously released management guidance.
Palavras-chave
Sobre autores
A. Emami
Hamadan University of Medical Sciences
Email: shahbazi.taha@yahoo.com
Iran, Hamadan
S. Yeganeh
Neurosurgery Research Group (NRG), Student Research Committee,Hamadan University of Medical Sciences
Email: shahbazi.taha@yahoo.com
Iran, Hamadan
H. Mohammadi
Student Research Committee, Hamadan University of Medical Sciences, School of Medicine
Email: shahbazi.taha@yahoo.com
Iran, Hamadan
T. Shahbazi
Neurosurgery Research Group (NRG), Student Research Committee,Hamadan University of Medical Sciences
Autor responsável pela correspondência
Email: shahbazi.taha@yahoo.com
Iran, Hamadan
Bibliografia
- Belot A., Antona D., Renolleau S. et al. SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May // Eurosurveillance. 2020. V. 25. Art. 2001010.
- Burnham J.P., Kollef M.H. Understanding toxic shock syndrome // Inten. Care Med. 2015. V. 41. P. 1707–1710.
- Burns J.C., Franco A. The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease // Exp. Rev. Clin. Immunol. 2015. V. 11. P. 819–825.
- Burns J.C., Kushner H.I., Bastian J.F. et al. Kawasaki disease: a brief history // Pediatrics. 2000. V. 106 (2). P. E27.
- Burns J.C., Mason W.H., Glode M.P. et al. Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease // J. Pediatrics. 1991. V. 118. P. 680–686.
- Carter M.J., Fish M., Jennings A. et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection // Nature medicine. 2020. V. 26. P. 1701–1707.
- Choi N.H., Fremed M., Starc T. et al. MIS-C and cardiac conduction abnormalities // Pediatrics. 2020. V. 146 (6). Art. e2020009738.
- Cirks B.T., Rowe S.J., Jiang S.Y. et al. Sixteen weeks later: expanding the risk period for multisystem inflammatory syndrome in children // J. Pediatr. Infect. Dis. Soc. 2021. V. 10. P. 686–690.
- Davies P., Evans C., Kanthimathinathan H.K. et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study // The Lancet Child Adolescent Health. 2020. V. 4. P. 669–677.
- Dolhnikoff M., Ferranti J.F., de Almeida Monteiro R.A. et al. SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome // Lancet Child Adol. Health. 2020. V. 4 (10). P. 790–794.
- Domico M., McCanta A.C., Hunt J.L. et al. High-grade heart block requiring transvenous pacing associated with multisystem inflammatory syndrome in children during the COVID-19 pandemic // HeartRhythm Case Rep. 2020. V. 6. P. 811–814.
- Dufort E.M., Koumans E.H., Chow E.J. et al. Multisystem inflammatory syndrome in children in New York State // New England J. Med. 2020. V. 383. P. 347–358.
- Eleftheriou D., Levin M., Shingadia D. et al. Management of Kawasaki disease // Arch. Dis. Childhood. 2014. V. 99. P. 74–83.
- Espitia C., Cervera I., González R., Mancilla R. A 38-kD Mycobacterium tuberculosis antigen associated with infection. Its isolation and serologic evaluation // Clin. Exp. Immunol. 1989. V. 77. P. 373–377.
- Feldstein L.R., Rose E.B., Horwitz S.M. et al. Multisystem inflammatory syndrome in US children and adolescents // New England J. Med. 2020. V. 383. P. 334–346.
- Feldstein L.R., Tenforde M.W., Friedman K.G. et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19 // Jama. 2021. V. 325. P. 1074–1087.
- Gamez-Gonzalez L.B., Moribe-Quintero I., Cisneros-Castolo M. et al. Kawasaki disease shock syndrome: unique and severe subtype of Kawasaki disease // Pediatr. Internat. 2018. V. 60. P. 781–790.
- Gatterre P., Oualha M., Dupic L. et al. Kawasaki disease: an unexpected etiology of shock and multiple organ dysfunction syndrome // Inten. Care Med. 2012. V. 38. P. 872–878.
- Godfred-Cato S., Bryant B., Leung J. et al. COVID-19-associated multisystem inflammatory syndrome in children – United States, March–July 2020 // Morb. Mortal. Wkly Rep. (MMWR). 2020. V. 69 (32). P. 1074–1080.
- Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 // Royal College of Paediatrics and Child Health (RCPCH). 2020. 6 p.
- Hajjeh R.A., Reingold A., Weil A. et al. Toxic shock syndrome in the United States: surveillance update, 1979–1996 // Emerg. Infect. Dis. 1999. V. 5 (6). P. 807–810.
- Hanson K.E., Caliendo A.M., Arias C.A. et al. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19 // Clin. Infect. Dis. 2020. Art. ciaa760.
- Henter J.-I., Horne A., Aricó M. et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis // Pediatr. Blood Cancer. 2007. V. 48. P. 124–131.
- Jiang L., Tang K., Levin M. et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents // Lancet Infect. Dis. 2020. V. 20. P. e276–e288.
- Kanegaye J.T., Wilder M.S., Molkara D. et al. Recognition of a Kawasaki Disease Shock Syndrome // Pediatrics. 2009. V. 123 (5). P. e783–e789.
- Lee P.Y., Day-Lewis M., Henderson L.A. et al. Distinct clinical and immunological features of SARS–CoV-2–induced multisystem inflammatory syndrome in children // J. Clin. Invest. 2020. V. 130. P. 5942–5950.
- McCrindle B.W., Rowley A.H., Newburger J.W. et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association // Circulation. 2017. V. 135 (17). P. e927–e999.
- Molloy E.J., Nakra N., Gale C. et al. Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management // Pediatr. Res. 2022. P. 1–10.
- Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19) // Centers for Disease Control and Prevention. 2020.
- Nakra N.A., Blumberg D.A., Herrera-Guerra A., Lakshminrusimha S. Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management // Children. 2020. V. 7. P. 69.
- Nasrabadi T., Ruegner H., Sirdari Z.Z. et al. Using total suspended solids (TSS) and turbidity as proxies for evaluation of metal transport in river water // Appl. Geochem. 2016. V. 68. P. 1–9.
- Newburger J.W., Takahashi M., Gerber M.A. et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association // Circulation. 2004. V. 110. P. 2747–2771.
- Pang J., Boshier F.A., Alders N. et al. SARS-CoV-2 polymorphisms and multisystem inflammatory syndrome in children // Pediatrics. 2020. Art. 146.
- Parthasarathy P., Agarwal A., Chawla K. et al. Upcoming biomarkers for the diagnosis of Kawasaki disease: a review // Clin. Biochem. 2015. V. 48. P. 1188–1194.
- Radia T., Williams N., Agrawal P. et al. Multi-system inflammatory syndrome in children, adolescents (MIS-C): a systematic review of clinical features and presentation // Paediatr. Resp. Rev. 2021. V. 38. P. 51–57.
- Riphagen S., Gomez X., Gonzalez-Martinez C. et al. Hyperinflammatory shock in children during COVID-19 pandemic // The Lancet. 2020. V. 395. P. 1607–1608.
- Rosenberg J., Gokaldas R., Gualberto G. Hemophagocytic lymphohistiocytosis (HLH)/macrophage activated syndrome (MAS) with CNS Aspergillus // Neurology. 2017. V. 88. Art. P2. 372.
- Shulman S.T. Pediatric coronavirus disease-2019-associated multisystem inflammatory syndrome. US: Oxford University Press, 2020. P. 285–286.
- Singh S., Jindal A.K., Pilania R.K. Diagnosis of Kawasaki disease // Int. J. Rheum. Dis. 2018. V. 21. P. 36–44.
- Son M.B.F., Friedman K. COVID-19: Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis // upToDate. Waltham. (Accessed on August 19, 2021). 2021.
- Son M.B.F., Friedman K., Kaplan S.L. et al. COVID-19: multisystem inflammatory syndrome in children (MIS-C) management and outcome // upToDate. 2021.
- Sperotto F., Friedman K.G., Son M.B.F. et al. Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach // Eur. J. Pediatrics. 2021. V. 180. P. 307–322.
- Talkington D.F., Schwartz B., Black C.M. et al. Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome // Infect. Immun. 1993. V. 61. P. 3369–3374.
- Terpos E., Gavriatopoulou M., Ntanasis-Stathopoulos I. et al. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment // Blood Cancer J. 2021. V. 11. P. 1–9.
- Whittaker E., Bamford A., Kenny J. et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 // Jama. 2020. V. 324. P. 259–269.
- Wu C.M.Y., Noska A. Intrauterine device infection causing concomitant streptococcal toxic shock syndrome and pelvic abscess with Actinomyces odontolyticus bacteraemia // BMJ Case Rep. 2016. Art. bcr2015213236.